Currently, there are limited options for patients with metastatic renal cell cancer who also have bone metastases. Bone metastases are related to a higher incidence of skeletal complications, including skeletal pain, fractures, spinal cord compression, and an increase in the amount of calcium in blood. Such skeletal complications could result in radiation or surgery to the bone. Since radium-223 is shown to be effective for patients with metastatic prostate cancer who also have bone metastases, researchers want to explore radium-223 with VEGF-targeting therapies to understand how the drug combinations affect safety, quality of life, incidence of skeletal complications, and the progression of cancer.